RE:RE:Yesterday's big volume on the TSX Sometimes it takes an outsiders objective view to finally convince a company of the merits and pitfalls of their various business strategies and how they should frame and discuss them broadly and to the market. PL probably brought some of that along and maybe he needed LSA as the outsider to push it to a new level, which the new pitch surely is. It could be it was mostly the LSA outsider view that did a lot of this as they are paid to know what industry best practice looks like for programs like what THTX is attempting to do.
We still need the hard data (walk the walk) but they are beginning to talk the talk on the value of their science in the new deck. There were various new turn-of-phrases that showed them puffing their chest out a bit on the science. I don't recall them offhand but as I was reading it I noted they hadn't said those things like that before. A bit more boastful on the science which sounded a lot more confident. I also noticed a lot more papers sited to back up the science in the footnotes One was even from the lead Dr at MD Anderson doing the study (F Meric-?). So once they can truly walk the walk, I habe hopes it will all come together convincingly for new investors to jump on the bandwagon.
qwerty22 wrote:
It's almost like they've now remembered to do what they forgot to do for the past 2 years.
Having said that though it definitely feels like we are reaching a turning point. You identified the company going through a transition, with all the changes Paul is implimenting it feels almost like a re-structuring. Maybe that's over-stating things. With clarity on the R&D assets and Paul implementing his changes it feels like we are reaching the end of that process.
I'm not sure selling the re-structuring process is as easy or profitable as selling what comes out of it.
SPCEO1 wrote: I suspect the reason we saw big volume yesterday on the TSX (beating the volume on NASDAQ for the first time in recent memory) is because TH was likely speaking with analysts and portfolio managers in Canada the last couple of days and now is moving to the US via Cantor. Whenever they put out a new corporate presentation, you pretty much know they are starting an analyst/PM tour.
Given that TH has now sorted out its strategy re: cancer and NASH, an analyst/PM tour makes sense to explain that. Apparently, they got at least one or two Canadian institutions they visited with to buy, which is good. Hopefully, they have even better success in the US. And even more hopefully, they will get the Cantor analyst to pick up coverage on them. If some of Cantor's clients are intrigued by what they hear today, that will certainly increase the odds of Cantor picking up coverage, but those odds are likely still not fantastic.